Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
154 hedge funds and large institutions have $157M invested in Antares Pharma, Inc. in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 55 increasing their positions, 47 reducing their positions, and 24 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 160 → 154 (-6)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
50% less capital invested
Capital invested by funds: $312M → $157M (-$155M)
58% less call options, than puts
Call options by funds: $262K | Put options by funds: $628K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$3.4M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.94M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$1.83M |
| 4 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$1.73M |
| 5 |
JP Morgan Chase
New York
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$6.36M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$3.44M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$2.55M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.84M |
| 5 |
Goldman Sachs
New York
|
-$1.7M |
ATRS Hedge Fund Activity: Q1 2020 in Review
154 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2020, worth a combined $157M — down 50% from $312M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATRS and 21 opened new positions — a net loss of 3 holders — while 47 trimmed existing stakes and 55 added.
The largest buyer was Intrinsic Edge Capital Management, opening a new position worth an estimated $3.4M. The largest seller was MYCIO Wealth Partners, exiting entirely with an estimated $6.36M sold.
- 154 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2020, down from 160 in Q4 2019.
- Funds reported $157M of Antares Pharma, Inc. stock for Q1 2020, down 50% quarter-over-quarter.
- 21 funds opened new Antares Pharma, Inc. positions in Q1 2020 and 24 closed out, a net change of -3 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2020 was Intrinsic Edge Capital Management, an estimated $3.4M added.
- The largest Antares Pharma, Inc. seller in Q1 2020 was MYCIO Wealth Partners, an estimated $6.36M sold.
Based on aggregated 13F filings for Q1 2020.